Olema Oncology
San Francisco, California, United States
Naseem Zojwalla, M.D. is currently the Chief Medical Officer of Olema Oncology and has more than 15 years of experience in oncology and clinical development within both the biopharmaceutical industry and academia. Prior to joining Olema, Dr. Zojwalla served as Vice President of Clinical Development at Turning Point Therapeutics and earlier at Peloton Therapeutics (acquired by Merck) where she headed clinical development and strategy leading to the first-in-class approval of Welireg® (belzutifan) for the treatment of VHL disease.
Earlier in her career, she held roles of increasing responsibility leading clinical programs at multiple oncology-focused companies, including Onyx Pharmaceuticals, ImClone Systems, and Eisai Medical Research. A hematologist/oncologist by training, Dr. Zojwalla was previously an assistant clinical professor of medicine at Columbia University Medical Center. She received her Bachelor of Science degree from Stanford University and her M.D. from Temple University School of Medicine and completed her hematology/oncology fellowship training at Columbia University Medical Center.
Disclosure(s): Ownership Interest: I have received future stock options from the Commercial entity: Arcus Oncology (Ongoing); Olema Oncology (Ongoing)
Ownership Interest: I own stocks of the Commercial entity: Arcus Oncology (Ongoing); Olema Oncology (Ongoing)
Royalty: Peloton Therapeutics (Ongoing)
Salary or Employment Relationship (does not included small non-employed consulting arrangements): Olema Oncology (Ongoing)